A Phase 3 interventional study of Human Normal Immunoglobulin for Subcutaneous Administration in Primary Immune Deficiency, sponsored by CSL Behring. Completed at 13 sites in United States. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-01-25.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one has the largest enrollment of the 13 interventional ones that give a count, is the only one that started in 2006, is one of 9 in phase 3, and was the 3rd registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 25 across the 13 interventional studies, 27 across the 1 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).
The entire study consists of a 12-week wash-in/wash-out period followed by a 12-month treatment period. Pharmacokinetic (PK) parameters were assessed in a sub-group of subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
Biological: Human Normal Immunoglobulin for Subcutaneous Administration
Also known as: Hizentra
Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)
The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.
Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)
Evaluate non-inferiority of steady-state IgG area under the concentration-time curves standardized to a 7-day period (sAUCs) for subcutaneous immunoglobulin (SCIG) (IgPro20) versus the sAUC under intravenous immunoglobulin (IVIG) (Privigen) treatment. The sAUC under IVIG was taken from the same subjects in a preceding study (either ZLB03_002CR \[NCT00168025\] or ZLB05_006CR \[NCT00322556\]).
Time frame: Measured during a single dosing interval after at least 12 weeks of stable subcutaneous (SC) dosing with IgPro20 treatment
Annualized Rate of Clinically Documented SBIs (ITT Population)
The annualized rate was based on the total number of SBIs and the total number of subject study days during the study for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.
Time frame: For the duration of the study, up to 15 months
Annualized Rate of Clinically Documented SBIs (PPE Population)
The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.
Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
Annualized Rate of Infection Episodes
The annualized rate was based on the total number of infection episodes occurring during the efficacy period (N = 96) divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: Efficacy period: up to 12 months (week 13 to completion visit)
Number of Infection Episodes (Serious and Non-serious)
Total number of infections for the specified analysis population
Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections
The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection (N = 71), and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections
Total number of days out of work / school / kindergarten / day care or unable to perform normal daily activities due to infections, for the specified analysis population
Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
Annualized Rate of Hospitalization Due to Infection
The annualized rate was based on the total number of days of hospitalization due to infection (N = 7) and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
Number of Days of Hospitalization Due to Infections
Total number of days of hospitalization due to infections for the specified analysis population
Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
Use of Antibiotics for Infection Prophylaxis and Treatment
Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.
Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
Total Serum IgG Trough Levels
The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.
Time frame: Every 4 weeks, throughout the 12-month efficacy period
Maximum Concentration (Cmax) of Total Serum IgG at Steady State
Time frame: Week 28 ± 1 week of the treatment period
Tmax at Steady State
Timepoint of maximum concentration (Cmax)
Time frame: Week 28 ± 1 week of the treatment period
Minimum Concentration (Cmin) of Total Serum IgG at Steady State
Time frame: Week 28 ± 1 week of the treatment period
Rate of All AEs by Relatedness and Seriousness
The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Time frame: For the duration of the study, up to 15 months
Rate of Mild, Moderate, or Severe Local Reactions
In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of injection site reaction, injection site bruising, infusion site scab, injection site cyst, injection site eczema, injection site irritation, injection site nodule, and injection site pain. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
Time frame: For the duration of the study, up to 15 months
A total of 12 centers in the United States enrolled subjects for this study.
| Milestone | IgPro20 |
|---|---|
| Started | 49 |
| Completed | 38 |
| Not completed | 11 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Adverse event | 2 |
| Withdrew: Disqualifying laboratory results | 1 |
| Milestone | IgPro20 |
|---|---|
| Started | 38 |
| Completed | 28 |
| Not completed | 10 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Non-compliance | 1 |
| Withdrew: Termination of study site | 1 |
The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.
| SBIs per subject year | IgPro20 |
|---|---|
| Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population) | 0.00 |
Evaluate non-inferiority of steady-state IgG area under the concentration-time curves standardized to a 7-day period (sAUCs) for subcutaneous immunoglobulin (SCIG) (IgPro20) versus the sAUC under intravenous immunoglobulin (IVIG) (Privigen) treatment. The sAUC under IVIG was taken from the same subjects in a preceding study (either ZLB03_002CR \[NCT00168025\] or ZLB05_006CR \[NCT00322556\]).
| days*g/L | IgPro20 (PK Substudy) | IVIG (Privigen; Previous Study) |
|---|---|---|
| Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG) | 105.6 ± 31.56 | 103.2 ± 20.00 |
The annualized rate was based on the total number of SBIs and the total number of subject study days during the study for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.
| SBIs per subject year | IgPro20 |
|---|---|
| Annualized Rate of Clinically Documented SBIs (ITT Population) | 0.00 |
The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days. Potential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.
| SBIs per subject year | IgPro20 |
|---|---|
| Annualized Rate of Clinically Documented SBIs (PPE Population) | 0.00 |
The annualized rate was based on the total number of infection episodes occurring during the efficacy period (N = 96) divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
| infection episodes per subject year | IgPro20 |
|---|---|
| Annualized Rate of Infection Episodes | 2.76 (2.235 to 3.370) |
Total number of infections for the specified analysis population
| infections | IgPro20 |
|---|---|
| Number of Infection Episodes (Serious and Non-serious) | 96 |
The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection (N = 71), and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
| days per subject year | IgPro20 |
|---|---|
| Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections | 2.06 |
Total number of days out of work / school / kindergarten / day care or unable to perform normal daily activities due to infections, for the specified analysis population
| days | IgPro20 |
|---|---|
| Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections | 71 |
The annualized rate was based on the total number of days of hospitalization due to infection (N = 7) and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
| days per subject year | IgPro20 |
|---|---|
| Annualized Rate of Hospitalization Due to Infection | 0.20 (0 to 7) |
Total number of days of hospitalization due to infections for the specified analysis population
| days | IgPro20 |
|---|---|
| Number of Days of Hospitalization Due to Infections | 7 |
Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.
| days per subject year | IgPro20 |
|---|---|
| Use of Antibiotics for Infection Prophylaxis and Treatment | 48.52 |
The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.
| g/L | IgPro20 |
|---|---|
| Total Serum IgG Trough Levels | 12.53 ± 3.21 |
| g/L | IgPro20 (PK Substudy) |
|---|---|
| Maximum Concentration (Cmax) of Total Serum IgG at Steady State | 16.16 ± 4.93 |
Timepoint of maximum concentration (Cmax)
| days | IgPro20 (PK Substudy) |
|---|---|
| Tmax at Steady State | 3.118 ± 1.7729 |
| g/L | IgPro20 (PK Substudy) |
|---|---|
| Minimum Concentration (Cmin) of Total Serum IgG at Steady State | 13.70 ± 4.39 |
The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
| AEs per infusion | IgPro20 |
|---|---|
| All | 0.773 |
| At least possibly related | 0.634 |
| Serious | 0.004 |
| At least possibly related and serious | 0 |
In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of injection site reaction, injection site bruising, infusion site scab, injection site cyst, injection site eczema, injection site irritation, injection site nodule, and injection site pain. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
| local reactions per infusion | IgPro20 |
|---|---|
| All | 0.592 |
| Mild | 0.553 |
| Moderate | 0.038 |
| Severe | 0.002 |
Collected over Approximately 15 months (including the 3 month wash in/wash out period and the 12 month efficacy period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro20 | — | 7/49 (14.3%) | 49/49 (100%) |
| Event | IgPro20 |
|---|---|
| Chest painGeneral disorders | 2/49 |
| GastroenteritisInfections and infestations | 1/49 |
| Small intestinal obstructionGastrointestinal disorders | 1/49 |
| Tooth abscessInfections and infestations | 1/49 |
| CellulitisInfections and infestations | 1/49 |
| Urinary tract infectionInfections and infestations | 1/49 |
| Haemoglobin decreasedInvestigations | 1/49 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 1/49 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/49 |
| Event | IgPro20 |
|---|---|
| Injection site reactionGeneral disorders | 49/49 |
| SinusitisInfections and infestations | 14/49 |
| HeadacheNervous system disorders | 13/49 |
| NasopharyngitisInfections and infestations | 11/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/49 |
| DiarrhoeaGastrointestinal disorders | 7/49 |
| BronchitisInfections and infestations | 6/49 |
| FatigueGeneral disorders | 6/49 |
| Abdominal pain upperGastrointestinal disorders | 5/49 |
| Acute sinusitisInfections and infestations | 5/49 |
| Age Continuous(years) | IgPro20 |
|---|---|
| Mean | 34.4 ± 20.09 |
| Age, Customized(participants) | IgPro20 |
|---|---|
| 2 to < 12 years | 3 |
| 12 to < 16 years | 7 |
| 16 to < 65 years | 33 |
| ≥ 65 years | 6 |
| Sex: Female, Male(Participants) | IgPro20 |
|---|---|
| Female | 27 |
| Male | 22 |
| Race/Ethnicity, Customized(participants) | IgPro20 |
|---|---|
| Black or African American | 3 |
| White | 46 |
| Type of Primary Immunodeficiency(participants) | IgPro20 |
|---|---|
| Common variable immunodeficiency (CVID) | 46 ± 21.24 |
| X-linked agammaglobulinemia (XLA) | 3 |
The record gives a start of Nov 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hizentra
Primary Immunodeficiency Diseases →